Literature DB >> 19037720

Pilot study assessing HIV vaccine trial readiness among female sex workers, injection and non-injection drug users, and men who have sex with men in Spain.

María Florencia Etcheverry1, Elisa de Lazzari, Jonathan D Fuchs, Mercé Meroño, Ernesto Sierra, Jorge Del Romero, Jennifer L Evans, Eva Mendez-Arancibia, Constanza Jacques, Daniela Rojas, Marta Segú, José María Gatell, Joan Joseph.   

Abstract

The purpose of this study was to assess HIV risk and willingness to participate in HIV vaccine trials in three high risk populations in Spain. Eight hundred and forty-four participants, comprising female sex workers, injection and non-injection drug users (IDUs and NIDUs, respectively), and men who have sex with men were tested for HIV and surveyed for risk and willingness to participate in future preventive HIV vaccine trials. HIV seroprevalence was 3.8% (95% CI: 2-11). HIV infection was associated with transgender identification, IDU in the past year, and sex with an IDU or other drug-using partner. The majority (82%) expressed their willingness to participate in HIV vaccine trials. Substantial sexual and parenteral risk in all groups and concomitant willingness to participate in vaccine trials was found, particularly among women and IDUs. Additional longitudinal cohort studies in Spain are needed to plan future vaccine efficacy trials.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19037720     DOI: 10.1007/s10461-008-9486-x

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  9 in total

1.  HIV vaccine trial willingness among injection and non-injection drug users in two urban centres, Barcelona and San Francisco.

Authors:  M Florencia Etcheverry; Paula J Lum; Jennifer L Evans; Emilia Sanchez; Elisa de Lazzari; Eva Mendez-Arancibia; Ernesto Sierra; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Vaccine       Date:  2011-01-15       Impact factor: 3.641

2.  Are young injection drug users ready and willing to participate in preventive HCV vaccine trials?

Authors:  Vivian Levy; Jennifer L Evans; Ellen S Stein; Peter J Davidson; Paula J Lum; Judith A Hahn; Kimberly Page
Journal:  Vaccine       Date:  2010-07-16       Impact factor: 3.641

3.  Enhanced retention strategies and willingness to participate among hard-to-reach female sex workers in Barcelona for HIV prevention and vaccine trials.

Authors:  M Florencia Etcheverry; Jennifer L Evans; Emilia Sanchez; Eva Mendez-Arancibia; Mercé Meroño; José M Gatell; Kimberly Page; Joan Joseph
Journal:  Hum Vaccin Immunother       Date:  2013-01-04       Impact factor: 3.452

4.  Willingness to participate in HIV therapeutic vaccine trials among HIV-infected patients on ART in China.

Authors:  Yuan Dong; Xiaoxing Shen; Ruizhang Guo; Baochi Liu; Lingyan Zhu; Jing Wang; Linxia Zhang; Jun Sun; Xiaoyan Zhang; Jianqing Xu
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

5.  Willingness to Participate in Hypothetical HIV Vaccine Trial and Associated Factors among People Who Inject Drugs in Dar es Salaam, Tanzania.

Authors:  Masunga K Iseselo; Edith A M Tarimo; Eric Sandstrom; Asli Kulane
Journal:  Biomed Res Int       Date:  2020-07-02       Impact factor: 3.411

6.  Acceptability of a hypothetical preventative HIV vaccine among people who use drugs in Vancouver, Canada.

Authors:  Taylor Fleming; Jenna Valleriani; Cara Ng; Lisa Maher; Will Small; Ryan McNeil
Journal:  BMC Public Health       Date:  2020-07-09       Impact factor: 3.295

7.  HIV seroprevalence in five key populations in Europe: a systematic literature review, 2009 to 2019.

Authors:  Annemarie Rinder Stengaard; Lauren Combs; Virginie Supervie; Sara Croxford; Sarika Desai; Ann K Sullivan; Stine Finne Jakobsen; Quenia Santos; Daniel Simões; Jordi Casabona; Jeffrey V Lazarus; John B F de Wit; Frank M Amort; Anastasia Pharris; Lina Nerlander; Dorthe Raben
Journal:  Euro Surveill       Date:  2021-11

8.  Recruitment using respondent driven sampling, risk behaviors assessment and willingness of young female sex workers (18-25 years) in Dar Es Salaam, Tanzania to participate in HIV vaccine trials.

Authors:  Theodora Mbunda; Edith A M Tarimo; Muhammad Bakari; Eric Sandström; Asli Kulane
Journal:  BMC Public Health       Date:  2019-11-20       Impact factor: 3.295

9.  Population estimation and harm reduction among people who inject drugs in Addis Ababa, Ethiopia.

Authors:  Negussie Deyessa; Bekele Senbete; Aman Abdo; Bernard M Mundia
Journal:  Harm Reduct J       Date:  2020-09-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.